SEARCH

SEARCH BY CITATION

References

  • Robertson KA, nalepa G, Yang FC, Bowers DC, Ho CY, Hutchins GD, Croop JM, Vik Ta, Denne SC, Parada LF, Hingtgen CM, Walsh LE, Yu M, Pradhan KR, Edwards-Brown MK, Cohen MD, Fletcher JW, Travers JB, Staser KW, Lee MW, Sherman MR, Davis CJ, Miller LC, Ingram DA, Clapp DW. 2012. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol 13: 12181224.
  • Yang FC, Ingram DA, Chen S, Zhu Y, Yuan J, Li X, Yang X, Knowles S, Horn W, Li Y, Zhang S, Yang X, Vakili St, Yu M, Burns D, Robertson K, Hutchins G, Parada LF, Clapp DW. 2008. Nf1-dependent tumors require a Microenvironment containing Nf1+/−- and c-kit-dependent bone marrow. Cell 135: 34373448.
  • Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. 2002. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 296: 920922.